Navigation Links
Transave, Inc. Secures $12.5 Million in New Financing
Date:10/2/2008

thcare.

"This financing, in addition to a $35M Series D financing closed in March, will enable us to complete our Arikace Phase II program for the treatment of Pseudomonas infections in cystic fibrosis patients," said Tim Whitten, Transave's chief executive officer. "It also allows us to broaden the Arikace clinical trial program by initiating a Phase II clinical trial in a second area of high unmet need: bronchiectasis patients who have pseudomonas lung infections."

Based on the strength of the Arikace clinical profile to date, the company has initiated a Phase II trial to evaluate the compound for treating Pseudomonas infections in patients with non-cystic fibrosis-related bronchiectasis in Europe and India. The U.S. Food and Drug Administration (FDA) has also agreed to the company's plans to expand this trial into the United States. Bronchiectasis is the permanent widening of the bronchi (the large tubes which begin at the bottom of the trachea and branch into the lungs). Individuals with bronchiectasis are vulnerable to recurrent respiratory infections, which often have a Pseudomonas component.

Kristen Kosofsky, managing director of Horizon, noted, "Our goal at Horizon is to support the growth and success of innovative companies like Transave that develop important next-generation technologies that serve as the cornerstone for improving human health and quality of life."

About Arikace (liposomal amikacin for inhalation)

Arikace is a form of the antibiotic amikacin that is enclosed in nanocapsules of lipid called liposomes. This proprietary next-generation liposomal technology prolongs release of amikacin in the lung while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micrometers), neutrally-charged liposomes that enable biofilm penetration and are highly efficient, with very low lipid-to-drug ratio (0.65). Arikace can be effectively delivered thr
'/>"/>

SOURCE Transave, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
2. Northwest Secures US$1.0 Million Debt Financing
3. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
4. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
5. Progenitor Cell Therapy Secures Industry Accreditation
6. BIOCOM Institute Secures Non-Profit Designation and Funding
7. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
8. OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies
9. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
10. Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
11. Veran Medical Technologies Secures $4.75M in First Institutional Funding

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...omputing promises ultra-fast communication, comput...information. But trying to use quantum states as c...siness. Now two physicists have shown, mathematica...ntum communication, while keeping the information ...e of Physical Review Letters and highlighted wit...
(Date:11/23/2009)...SISSAUGA,ON,Nov.23/PRNewswire-FirstCall/-YMBioScie...ctdevelopmentcompanythatidentifiesandadvancesadive...iousstagesofdevelopment,todayreportedthatCytopia(A...uatingCYT387,apotent,orally-administeredJAK1/JAK2i...hester,Minnesota.AproposaltomergeCytopiaintoYMhasb...
(Date:11/23/2009)...TTLE,Nov.23/PRNewswire/--ImmuneDesignC or p.(IDC)a...xecutiveChairman.Dr.Carterhasasuccessfultrackrec o... merChiefExecutiveOfficeratZymoGenetics,inSeattle,...gen,Denmark. ,, (Photo: http://www.newscom.com/...d,IDC,sfounderandChiefExecutiveOfficercommented,"I...
(Date:11/23/2009)...WOODCITY,Calif.,Nov.23/PRNewswire/--PearlTherapeut...uticproductsforthetreatmentofchronicrespiratorydis...ecompany,sBoardofDirectors.Mr.Rosenhas25yearsofexp...es,includingkeyrolesatGileadSciencesandALZACorpora...Pearl,sBoardtosix. ,, "Howiebringsawealthofprod...
Breaking Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Pearl Therapeutics Appoints Howie Rosen to Board of Directors 2
...harma, Inc. (Amex: DDD ) today announced that th...ued a Complete Response letter for its Abbreviated... The application, filed by SCOLR on August 5, 2008...ephedrine tablet based on its patented Controlled ...omplete Response letter requests additional inform...
...stCall/ - GeneNews Limited (TSX: GEN), a company f...or the early detection of diseases and personalize...n T. West has retired from the position of Chief F...easurer of GeneNews as of December 31, 2008. The B... to the role of Vice President of Finance and Trea...
...19 , - Tamiflu Remains Fully Effective Agains...urope , Latest surveillance data coming throug...ontrol (ECDC) from virologists and clinicians indi...ominant strain in Europe so far this,season. Based... the oral,antiviral Tamiflu (oseltamivir) is fully...
Other Biology Technology:FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine 2FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine 3GeneNews announces management changes 2Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain 2Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain 3Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain 4
(Date:11/23/2009)...ble for the H1N1 virus has been sent to vaccinate ...ion marks the first time vaccine has been sent to ...owa State University,s Hank Harris, professor of a...nd has been shipping preventive doses to swine pro...eks., The latest vaccines were shipped to a swin...
(Date:11/23/2009)...d USDA study concluded that 50 million U.S. acres ...ould be converted from current uses to the product...m which biomass could be harvested for use as a bi... a perennial grass monoculture from which substant...expected to require nitrogen fertilizer. , An ag...
(Date:11/23/2009)...microbiologist Louis Tisa has received two grants ...actinorhizal plants, widespread woody plants with ... soils. , The United States Department of Agric...ar, cellular and biomedical sciences, $399,000 to ...teria Frankia and Casuarina, an actinorhizal plant...
Breaking Biology News(10 mins):Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2UNH prof. receives nearly $500,000 to research environmentally significant plants 2Drug Shows Promise in Nervous System Tumor Treatment 51138 1Drug Shows Promise in Nervous System Tumor Treatment 51138 2Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums 51133 1Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums 51133 2Greater Language Skills in 20s May Guard Against Alzheimers 51128 1Greater Language Skills in 20s May Guard Against Alzheimers 51128 2Greater Language Skills in 20s May Guard Against Alzheimers 51128 3
... the Howard Hughes Medical Institute have succeede...y produced by a wide range of odors, including van...ealing these distinct ?but often overlapping ?patt...tep in understanding how the brain translates comp...o odor perception in the brain, the researchers sa...
...e to fathom a proverb ?catch the figurative meanin... According to research led by V. S. Ramachandran, ...the University of California, San Diego, a region ...y at least partly responsible for the human abilit...agues tested four right-handed patients with damag...
...e months after deciding to create an electronic da... registry and results database using an independen...mation on Roche’s clinical trials can be accessed .... This site is designed to give patients and healt...eed, in terms they can understand. , Ed Holdener, ...
Other Biology News:Decoding the logic of olfaction 2Decoding the logic of olfaction 3Decoding the logic of olfaction 4Grasping metaphors: UC San Diego research ties brain area to figures of speech 2Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3
...a for spontaneous ligand immobilization can be cou...tigen, or receptor to create an affinity matrix of...le ligands via primary amines. Affi-Gel 10 gel cou... 11; Affi-Gel 15 gel couples acidic proteins with ...
2,7-Dichlorofluorescein (Fluorescence Reference Standard) from AnaSpec
Rabbit Anti-Chicken IgY, IgG F(ab')2 fragment Antibody, Biotin Conjugated from Biomeda Corporation
Goat Anti-Human Presenilin 2 Antibody, Unconjugated from ABR-Affinity BioReagents
Biology Products: